Goldman Sachs rates Vaxcyte a buy with $135 price target, highlighting vaccine platform and pneumonia candidate. Read more ...

As we are approaching winter and there is an increase in respiratory diseases, it’s also important to know about pneumococcal ...

The following is a summary of “Evaluating Sex Differences in Pneumococcal Disease Burden and Vaccination Effectiveness in ...

Pneumonia is a lung infection that annually impacts millions of people around the globe, according to the Centers for Disease ...

Pneumonia can be caused by a virus, bacteria or fungus. Each of these can cause an immune reaction in the tissues of the ...